Ann Marie Navar

4 weeks ago | jamanetwork.com | Steven Nissen |Qiuqing Wang |Stephen Nicholls |Ann Marie Navar

Zerlasiran for the Treatment of Atherosclerotic Cardiovascular Disease—Reply Zerlasiran—A Small-Interfering RNA Targeting Lipoprotein(a) Steven E. Nissen, MD; Qiuqing Wang, MS; Stephen J. Nicholls, MBBS, PhD; Ann Marie Navar, MD, PhD; Kausik K. Ray, MD, MPhil; Gregory G. Schwartz, MD, PhD; Michael Szarek, PhD; Erik S. G. Stroes, MD, PhD; Roland Troquay, MD; Jannick A. N. Dorresteijn, MD, PhD; Henry Fok, MBBS, PhD; David A.

Dec 4, 2024 | jamanetwork.com | Henry Chen |Eric Peterson |Ann Marie Navar |Benjamin Chong

Incidence and Prevalence of Atherosclerotic Cardiovascular Disease in Cutaneous Lupus Erythematosus Key PointsQuestion  What is the incidence and prevalence of atherosclerotic cardiovascular disease (ASCVD) in persons with cutaneous lupus erythematosus (CLE) compared to the general population as well as persons with systemic lupus erythematosus and psoriasis?

Nov 18, 2024 | jamanetwork.com | Steven Nissen |Qiuqing Wang |Stephen Nicholls |Ann Marie Navar

Key PointsQuestion  What is the effect of zerlasiran on time-averaged lipoprotein(a) serum concentrations during 36 weeks of treatment? Findings  In 178 patients with cardiovascular disease and lipoprotein(a) concentrations greater than or equal to 125 nmol/L, the least-squares mean placebo-adjusted time-averaged percent change in lipoprotein(a) serum concentrations was −85.6%, −82.8%, and −81.3% for the 450 mg every 24 weeks, 300 mg every 16 weeks, and 300 mg every 24 weeks groups, respectively.

Aug 28, 2024 | medrxiv.org | Dylan Owens |Ann Marie Navar |Luiza Giuliani Schmitt

The authors have declared no competing interest. This study did not receive any fundingI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Aug 7, 2024 | jamanetwork.com | Ann Marie Navar |Kristen K. Patton

The Urgent Need to Improve Outcomes for Pregnant Cardiovascular Trainees Even as a small group of women in cardiology, we have collectively experienced infertility, miscarriage, stillbirth, low birth weight, preterm birth, and other pregnancy-related complications that affected both our health and the health of our children. Our experiences are unfortunately common among our peers.